Google DeepMind has unveiled a new "bioresilience program" aimed at helping governments and researchers prevent, detect and respond to biological threats, deepening the lab's dual-track effort to both guard against AI-enabled biorisks and deploy AI as a defensive tool. The initiative, launched in partnership with Alphabet-owned drug-discovery company Isomorphic Labs, seeks to improve pathogen surveillance, accelerate the design of vaccines and treatments, and strengthen outbreak response.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.